Effect of discontinuation and reduction of respiratory cotherapies on the effectiveness of CFTR modulators
Open Access
- 20 May 2026
- journal article
- Published by Elsevier in Journal of Cystic Fibrosis
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Impact of elexacaftor/tezacaftor/ivacaftor on utilization of routine therapies in cystic fibrosis: Danish nationwide register studyJournal of Cystic Fibrosis, 2024
- Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftorPediatric Pulmonology, 2024
- Health care resource utilization preceding death or lung transplantation in people with cystic fibrosisJournal of Cystic Fibrosis, 2024
- Standards for the care of people with cystic fibrosis; establishing and maintaining healthJournal of Cystic Fibrosis, 2023
- Use of cystic fibrosis inhaled medication before and after elexacaftor/tezacaftor/ivacaftor initiationJournal of Cystic Fibrosis, 2023
- Temporal trends in healthcare resource use and associated costs of patients with cystic fibrosisJournal of Cystic Fibrosis, 2022
- Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapyJournal of Cystic Fibrosis, 2020
- Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in FranceJournal of Cystic Fibrosis, 2020
- Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2 years of treatment with ivacaftor in a real-world settingJournal of Cystic Fibrosis, 2018
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009